Skip to Content

ECCO 2019: Vedolizumab vs adalimumab in patients with active ulcerative colitis

In this MEDtalk professor Stefan Schreiber presents a head-to-head study of the efficacy and safety of vedolizumab and adalimumab for treatment over 52 weeks in adults with moderately to severely active ulcerative colitis (UC). The first study to directly compare two biological agents in IBD. Click and hear the results.

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top